DIAdvisor

The DIAdvisor is a large scale- integrating project (IP) aiming at development of a prediction based tool which uses past and easily available information to optimise the therapy of type I and developed type II diabetes.

The DIAdvisor does not depend on specific sensor technologies and technologies like standard strip sensing, minimally invasive continuous glucose sensors and non-invasive methods.

For safety reason, the DIAdvisor system will be able to self-assess the confidence of its proposed decisions. For safety reasons as well as for the sake of therapy improvements the system connects and provides information and trends to the Health Care Provider.

Glucose prediction is difficult and requires advanced science. This can be achieved only by a well-balanced group of eminent experts including academics, clinicians, user representatives and leading companies. This includes physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding.

The expected impact of DIAdvisor will be improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs. Moreover, the project will constitute a valuable opportunity for European companies to build up a special know-how leading products that profoundly and positively impacts the lives of millions with other indications than diabetes.

For further information, please visit:
http://www.diadvisor.eu/

Project co-ordinator:
Novo Nordisk A/S (Denmark)

Partners:

  • Novo Nordisk A/S (Denmark),
  • Johannes Kepler Universität Linz (Austria),
  • Lunds Universitet (Sweden),
  • Universita Degli Studi di Padova (Italy),
  • Centre Hospitalier Regional Universitaire de Montpellier (France),
  • Toumaz Technology Ltd (UK),
  • Sensor Technology and Devices Ltd (UK),
  • Ondalys SARL (France),
  • Romsoft SRL (Romania),
  • Institut Klinicke a Experimentalni Mediciny (Czech Republic),
  • RICAM, Österreichische Akademie der Wissenschaften (Austria),
  • Rambøll Danmark A/S (Denmark),
  • Federation Internationale du Diabete Region Europe (Belgium)

Timetable: from 03/2008 – to 02/2012

Total cost: € 9.284.061

EC funding: € 7.099.992

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-HLTH-2021-TOOL-06-03: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

CSAM Acquires Optima - Further Boosts eH…

CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, today announced it has signed a deal to acquire eHealth player Optima Corporation Ltd from...

Novartis and Hewlett Packard Enterprise …

Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to...

COVID-19 Origins Still a Mystery

Scientists using computer modelling to study SARS-CoV-2, the virus that caused the COVID-19 pandemic, have discovered the virus is most ideally adapted to infect human cells - rather than bat...

Using Artificial Intelligence to Overcom…

Depression is a worldwide problem, with serious consequences for individual health and the economy, and rapid and effective screening tools are thus urgently needed to counteract its increasing prevalence. Now...

Deep Machine Learning Completes Informat…

The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has...

EU Digital COVID Certificate Enters into…

The EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across...

Philips and the Spanish National Center …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could...

Scottish Health and Care Professionals G…

Scottish health and care professionals across a wide range of clinical settings including NHS Scotland health boards are being given access to an individual's COVID-19 vaccine status through the Orion...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...